INVESTORS
About ALZAI Health
ALZAI delivers AI-driven Alzheimer’s Disease risk assessment completely non-invasively, using only pre-existing data found in every patient record.
ALZAI flags patients in the early stages of the disease or at risk of developing the disease in the coming years. This is how ALZAI enables early diagnosis, treatment, and preventive care.
Sensitivity detecting who will be diagnosed with Alzheimer’s.
Screening for disease risk up to 10 years out.
More sensitive than existing screening methods.
Biomarkers used, universally present in common medical records.
Real world patient medical records trained with AI.
|
Alzai Health Corp.
22 Adelaide St. West, Suite 3400, Toronto, Ontario, M5H 4E3, Canada Tel: +1 (416) 862-4351 Email: hayim@alzaihealth.com or roy@alzaihealth.com Website: www.alzaihealth.com |
|
|---|---|
|
Date of Formation:
|
November 15, 2024
|
|
Exchange/Ticker:
|
TSX-V: ALZI
|
|
Jurisdiction Where Formed:
|
Ontario, Canada
|
|
Financial Year End:
|
April 30
|
|
CUSIP:
|
02262P103
|
|
ISIN:
|
02262P1036
|
|
Industry Classification:
|
R&D in the physical, engineering and life sciences
|
|
Transfer Agent:
|
Odyssey Trust Company
|
|
Auditors:
|
Davidson & Company LLP
|
Visit SEDAR+ to search the System for Electronic Document Analysis and Retrieval to view company documents.
Read More
SEND US A MESSAGE
